Novogen Ltd. through its subsidiary, engages in the business of pharmaceutical research and development. It operates through four segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. The Drug Development segment includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. The Oncology Drug Program segment involves the development of selected oncology drug candidates which have indicated potential bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. The Consumer Business segment is a dietary supplement business based on red clover isoflavones which are marketed and sold world wide. The Wound Healing segment is a separate and unique technology based on Beta-1 Glucan to aid in the management of wounds. Novogen was founded in 1992 and is headquartered in Sydney, Australia.